BCRX: External innovation and disciplined growth drive rare disease portfolio expansion and profitability
A shift to external innovation and strategic acquisitions is driving pipeline expansion and profitability, with ORLADEYO and navenibart positioned for complementary growth. The company targets rare diseases with strong science and maintains a strict focus on sustained profitability.Based on BioCrys…